Literature DB >> 19910897

Molecular pathology of differentiated thyroid cancer.

A Greco1, M G Borrello, C Miranda, D Degl'Innocenti, M A Pierotti.   

Abstract

Thyroid cancer is the most common endocrine malignancy; it accounts for approximately 1% of all new case of cancer each year, and its incidence has increased significantly over the last few decades. The majority of thyroid tumors originate from follicular epithelial cells. Among them, papillary (PTC) and follicular carcinomas (FTC) represent the most common forms of differentiated thyroid cancer and account for approximately 80% and 15% of all cases, respectively. Specific genetic lesions are associated to each thyroid tumor histotype: BRAF mutations and RET/PTC and TRK oncogenes have been detected in PTC, whereas FTC is characterized by PAX8/PPARgamma rearrangements and RAS mutations. In this review we summarize studies on the molecular biology of the differentiated thyroid tumors, with particular interest in the associated genetic lesions and their role in thyroid carcinogenesis. We also report recent findings on gene expression and miRNA profiles of PTC and FTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910897

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  22 in total

Review 1.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

Review 2.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

3.  Association between microRNA polymorphisms and papillary thyroid cancer susceptibility.

Authors:  Gang Dong; Ruifang Zhang; Jingjing Xu; Yanfei Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Radiation dose rates of differentiated thyroid cancer patients after 131I therapy.

Authors:  Pingyan Jin; Huijuan Feng; Wei Ouyang; Juqing Wu; Pan Chen; Jing Wang; Yungang Sun; Jialang Xian; Liuhua Huang
Journal:  Radiat Environ Biophys       Date:  2018-03-10       Impact factor: 1.925

Review 5.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

6.  BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.

Authors:  Ahmet Şahpaz; Binnur Önal; Ahmet Yeşilyurt; Ünsal Han; Tuncay Delibaşı
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

7.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

8.  Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.

Authors:  Debora Degl'Innocenti; Chiara Alberti; Giancarlo Castellano; Angela Greco; Claudia Miranda; Marco A Pierotti; Ettore Seregni; Maria Grazia Borrello; Silvana Canevari; Antonella Tomassetti
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

9.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

10.  Hypoxia-inducible factor in thyroid carcinoma.

Authors:  Natalie Burrows; Muhammad Babur; Julia Resch; Kaye J Williams; Georg Brabant
Journal:  J Thyroid Res       Date:  2011-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.